CSIMarket
 
Lantern Pharma Inc   (LTRN)
Other Ticker:  
 
 
Price: $9.9600 $1.26 14.483%
Day's High: $10.7299 Week Perf: 29.35 %
Day's Low: $ 8.72 30 Day Perf: 148.38 %
Volume (M): 1,210 52 Wk High: $ 10.73
Volume (M$): $ 12,047 52 Wk Avg: $4.49
Open: $8.77 52 Wk Low: $2.38



 Market Capitalization (Millions $) 108
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 0

Lantern Pharma Inc
Lantern Pharma Inc is a biotechnology company that focuses on using artificial intelligence (AI) and machine learning (ML) in drug discovery and development. The company aims to improve the efficacy and success rate of cancer therapeutics by identifying novel biomarkers and repurposing existing FDA-approved drugs. Lantern Pharma's AI-driven platform helps to predict patient response to specific cancer treatments and enables precision medicine approaches. By leveraging big data analytics, Lantern Pharma aims to accelerate the identification and development of personalized therapies for cancer patients, ultimately leading to better patient outcomes.


   Company Address: 1920 McKinney Avenue Dallas 75201 TX
   Company Phone Number: 277-1136   Stock Exchange / Ticker: NASDAQ LTRN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Lantern Pharma Enhances Cancer Therapy Development with AI-Guided Drug Candidates and Expanding Data Points

Published Fri, Mar 15 2024 12:00 PM UTC

Lantern Pharma, an AI company focused on developing innovative cancer therapies through its proprietary AI and machine learning platform, RADR, has recently made significant progress in its drug development programs. This includes the dosing of the first patients in the Phase 1 clinical trial for Lantern's investigational new drug LP-284, designed for patients with relapsed ...

Product Service News

Lantern Pharma to Showcase Cutting-Edge AI-Driven Drug Discovery at Leading Virtual Conference

Published Tue, Mar 5 2024 1:01 PM UTC

In a powerful move towards revolutionizing cancer drug discovery, Lantern Pharma Inc. (NASDAQ: LTRN) is set to participate in H.C Wainwright & Co.'s 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference. The renowned conference, which will take place on Thursday, March 7th, promises to offer a platform for the discussion and presentation of...

Product Service News

Lantern Pharma's RADR A.I. Platform Surpasses 60 Billion Data Points, Fueling Cancer Therapy Innovations and Streamlining Development Timelines

Published Mon, Mar 4 2024 1:01 PM UTC

Lantern Pharma, a prominent player in AI-driven cancer drug discovery and development, recently achieved significant milestones concerning the growth, size, and progress of its proprietary AI platform called RADR. This development has huge implications for the transformation of oncology drug development, with Lantern Pharma aiming to establish a comprehensive, expansive, and...

Lantern Pharma Inc

Lantern Pharma Inc continues to face financial challenges as expenditures spike in Q2 2023, reporting an operating loss of $-5.19 million

Lantern Pharma Inc, a company in the Major Pharmaceutical Preparations industry, recently announced its second-quarter earnings for 2023. Unfortunately, the company reported an operating loss of $-5.190297 million, which is a decline from the $-4.394821 million loss in the same quarter of the previous year.
Analysts are now speculating on when Lantern Pharma Inc will be able to generate positive revenue. The company is implementing various corporate policies in an effort to ensure a consistent business performance. This is particularly important considering the growing deficit faced by the company, which has increased from $-4.492 million in the second quarter of 2022 to $-4.746 million in the present period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com